Business Context and Reporting Period
Company: electroCore, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2018
Reporting Period: Second quarter ended June 30, 2018
Business Overview: The Company develops and markets the gammaCore therapy, a non-invasive neuromodulation device. It is classified as an emerging growth company.
Key Financial Metrics
This Form 8-K serves as a notification of the issuance of a press release regarding financial results for the quarter ended June 30, 2018. The specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are contained in the press release furnished as Exhibit 99.1 and are not explicitly detailed within the text of this filing. Therefore, the filing text does not provide clear values for these metrics.
Material Changes and Operational Updates
- Regulatory Strategy: Based on existing clinical trial data, the Company expects to submit a Section 510(k) application to the U.S. Food and Drug Administration (FDA) before the end of 2018 to expand the gammaCore label for the prevention of cluster headache.
- Market Opportunity: The filing notes that there are currently no approved treatments for cluster headache prevention.
- Future Regulatory Steps: Following a potential FDA release for cluster headache prevention, the Company plans to submit a subsequent 510(k) to expand the label to the prevention of migraine headache in adults.
Guidance, Outlook, and Management Commentary
- Clinical Trials: The Company intends to initiate an additional pivotal trial for gammaCore for the prevention of migraine in the second half of 2018.
- Data Presentation: Management expects to present full data from its PREMIUM trial for the prevention of migraine at a medical congress before the end of 2018.
- Outlook: The Company maintains its strategic focus on expanding the therapeutic indications for gammaCore through regulatory submissions and clinical data presentation.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2018 financial figures (revenue, net loss, cash position).
- Monitor FDA acceptance and review status of the anticipated 510(k) submission for cluster headache prevention.
- Track the initiation timeline of the additional pivotal migraine prevention trial scheduled for the second half of 2018.
- Verify the date and venue for the presentation of PREMIUM trial data at the upcoming medical congress.